Trial Profile
Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA 2000 (Electroporation, EP)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs GLS 5300 (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions
- Sponsors GeneOne Life Science
- 10 Aug 2020 According to an Inovio Pharmaceuticals media release, interim results from this trial were presented at the American Society of Gene & Cell Therapy (ASGCT) Conference.
- 22 May 2020 Status changed from active, no longer recruiting to completed.
- 28 Apr 2020 According to an Inovio Pharmaceuticals media release, interim results from the trial have been selected for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Conference to be held virtually from May 12-15, 2020.